Efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the treatment of alopecia areata
Keywords:
Efficacy, tacrolimus, clobetasol propionate, alopecia areataAbstract
Objective To assess the efficacy of tacrolimus and clobetasol propionate in the treatment of alopecia areata. Methods A clinical trial was carried out in the department of Dermatology and Venereology, Dhaka Medical College Hospital, Dhaka, Bangladesh from May 2013 to April 2014. Total sixty patients were enrolled and divided into group A and group B. Thirty of group A patients were treated with topical tacrolimus and thirty of group B patients were treated with topical clobetasol propionate. Results In group A, the duration of illness ranged from 2 months to 36 months and in group B, from 1 month to 24 months. Among the patients of group A and B, 25 (83.3%) and 27 (90%) patients improved, respectively. After 16th week of treatment, slight response in 6 (20%) and 4 (13.3%) and moderate response in 18 (59.4%) and 22 (63.2%) and marked response in 1 (3.3%) and 1 (3.3%) was seen in group A and group B, respectively. No significant difference was observed (p value = 0.648). Conclusion Both the drugs, clobetasol propionate and tacrolimus when used individually, were found to be equally effective in the treatment of alopecia areata and tacrolimus ointment 0.1% can be used as an alternate therapeutic modality.References
Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011;4:107-15.
Tan E, Tay YK, GIam YC. A clinical study of childhood alopecia areata in Singapore. Pediatr Dermatol. 2002;19:298-301.
Tosti A, Bellavista S, Iorizzo M. Alopecia areata: A long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55:438-41.
Galán-Gutiérrez M, Rodríguez-Bujaldón A, Moreno-Giménez JC. Update on the treatment of alopecia areata. Actas Dermosifiliogr. 2009;100:266-76
Wang E, Lee JS, Tang M. Current treatment strategies in pediatric alopecia areata. Indian J Dermatol. 2012;57:459-65.
García Hernández MJ, Camacho Martínez F. Epidemiología clínica de la alopecia areata. Actas Dermosifiliogr. 2002;93:223-8.
MacDonald Hull SP, Wood ML, Hutchinson PE et al. British Association of Dermatologists. Guidelines for the management of alopecia areata. Br J Dermatol. 2003;149:692-9.
Mandani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549-66.
Ferrando J, Moreno-Arias GA. Multi-injection plate for intralesional corticosteroid treatment of patchy alopecia areata. Dermatol Surg. 2000; 26:690-1.
Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49:96-8.
Tosti A, Guidetti MS, Bardazzi F, Misciali C. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol. 1996;35:199-201.
Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol. 2005;52:138-9.
Saleem A, Khan M, Mashori GR et al. Comparison of effectiveness of topical tacrolimus and betamethasone with soft paraffin in the treatment of patchy alopecia areata. Pak J Med Sci. 2009;25:833-6.
Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol. 2006;20:1243-7.
Sotiriou E, Patsatsi A, Fotiadou C et al. Tacrolimus ointment 0.1% in the treatment of active patchy alopecia areata of childhood. Eur J Pediatr Dermatol. 2007;17: 227-30.